Thx again for this note
An interesting consequence of limiting Covid booster shots to those over 65 ( maybe lowered to those over 60 ) is the increased need for oral drugs to shorten the recovery time for those under 65 who get Covid ......especially those with break thru infections ,unlikely to be hospitalized but feel terrible anyway.
Initially I wasn't that impressed with the AVIR data mentioned in your post but after some DD today I've changed my mind especially considering the 2 day point into the trial data available so far.
AT527 does lower the viral load and shorten recovery time ...in the data so far .
The question thats relevant to AMRN ...is wether we will get that level of detail from P-IT 2
In PT-2 the outcome measures are hard data recordings ( which is what we need ) ie was there less death in the V arm , less hospitalization , alive and out of the hospital at 28 days etc
The inclusion criteria specifies ...without clear indication for hospitalization
So if most of these patients recover without being hospitalized .....are those on V recovering faster than those on placebo .
Is there any measurement of viral load for those that get Covid ...in the V arm vs placebo ..as viral load correlates to outcome .
Anyone know ?
If those under 65 aren't getting booster shots then there will be a need for a reasonably priced oral drug to shorten recovery time for at least the vaccinated that are unlikely to be hospitalized anyway
Kiwi
PS. quick note on China . China has been building ghost cities for years and these developers have been endlessly increasing their unsustainable debt loads. Some of these Co's will now disappear and with it the need some of the raw materials China has been importing to sustain this building boom . Chinese Govt is expected to contain the fallout ....but we see may reduced growth in Chinese economic activity at least short term.